Script Relief launched a new and improved HelpRx website that, according to the company, aims to provide a user-friendly experience and additional resources to people searching for prescription drug discounts, as well as information about medications.
The imminent entry of several companies — including big pharma, small biotech and generic participants — into the global biosimilars space will propel the market toward exponential growth. The market is expected to soar from $1.2 billion in 2013 to $24 billion in 2019, reported Frost & Sullivan in research released earlier this week.
The Biotechnology Industry Organization and the Indiana Health Industry Forum commended the Indiana Senate for passing legislation designed to create a pathway for the substitution of interchangeable biologic medicines.
Vulnerable patients, including seniors and cancer patients, suffer from lack of access to needed painkillers as efforts to combat diversion and misuse of controlled substances often result in drugs not getting into the hands of those who need them, according to a new pharmacist survey by the National Community Pharmacists Association.
Cardinal Health Foundation recently awarded more than $350,000 in grant funding to 29 nonprofit organizations that are dedicated to the fight against prescription drug abuse, the organization announced Wednesday.
The National Association of Chain Drug Stores has announced that in lead-up to a hearing of the Subcommittee on Health of the U.S. House of Representatives Committee on Energy and Commerce, it has submitted a statement emphasizing the important collaborative role that pharmacy plays in helping to ensure that prescription medications are used appropriately and that local communities are safe.
Sohm on Tuesday announced the U.S. launch of its umbrella brand SohMed, positioning the company in the generic over-the-counter medicines segment for indications of pain, fever, cold, antacid and alertness.
When it comes to laws and regulations, what happens in Europe stays in Europe generally, and doesn’t have much bearing on the United States. But a recent win in Europe for U.S. drug maker Hospira could have some implications for the United States as well.
The country's embryonic biosimilars industry scored a victory last month as the organization that runs the pension fund for California state employees announced its opposition to a state Senate bill provision that would impose special requirements on pharmacists who dispense follow-on biologics.
European regulators have approved the European Union's first biosimilar monoclonal antibody. The new product, made by U.S.-based Hospira, comes seven years after the approval of Europe's first biosimilar.